Study to Assess the Safety and Effectiveness of NMRA-335140-501
← catalyst calendarNCT06029439 · readout ≤ 315 d
Sponsored by Neumora Therapeutics, Inc. (industry) · NMRA — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
1,000estimated
Sites
178
Countries
Brazil, Bulgaria, Canada +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-10 | actual | When the study began enrolling |
| Primary completion | Jun 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2023-09-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Major Depressive Disorder
Intervention
- Drug: NMRA-335140 — also filed as BTRX-335140, CYM-53093, Navacaprant
Primary outcome
what the primary-completion date above is the date OFSafety and tolerability assessments based on Treatment Emergent Adverse Events (TEAEs) and validated clinical scales
measured Up to 54 Weeks
Permalink · NMRA's whole pipeline · Catalyst calendar · Every registered study · What changed